Not just snoring. Not just tiredness. A measurable disease that was quietly destroying the quality of every night I slept — until a single study, one night in a lab, changed everything. This is what the data shows. Including three years of follow-up.
Obstructive sleep apnea (OSA) is not just snoring — it's your airway collapsing repeatedly while you sleep, cutting off oxygen to your brain and heart. Severity is measured by AHI: apnea-hypopnea index, or breathing disruptions per hour. Mild is 5–14. Moderate is 15–29. Severe is 30+. My AHI at diagnosis was 98.3. My airway was collapsing nearly 100 times an hour, my oxygen dropped to 76%, and I achieved zero minutes of REM sleep during the diagnostic segment. CPAP therapy brought my average AHI to 0.83 — a 99% reduction. It has changed my life. GLP-1-driven weight loss appears to be improving the underlying disease further. I'm tracking that in real time. Not medical advice — educational.
Educational content only — not medical advice. This page documents personal experience and published research. Sleep apnea diagnosis and treatment decisions require a qualified sleep medicine specialist. Data from a clinical polysomnogram performed at St. Joseph Hospital Sleep Center, Orange, CA, April 2023.
Obstructive sleep apnea happens when the muscles in your throat relax during sleep and your airway partially or completely collapses. Your brain detects the drop in oxygen and sends an emergency signal to wake you up enough to reopen the airway. This happens so fast — and so many times — that most people have no conscious memory of it. You just wake up exhausted, wondering why.
OSA is not an obesity-exclusive disease. Anatomy matters — jaw structure, neck circumference, tongue size. But excess weight is the single largest modifiable risk factor for OSA, and for many people carrying significant weight, the relationship is direct: more tissue around the airway equals more collapse risk, especially in the supine position. My supine AHI at diagnosis was 114.1. On my side it was 92.6. Every sleeping position was severe.
The consequences extend well beyond feeling tired. Untreated severe OSA is associated with hypertension, atrial fibrillation, cardiovascular disease, type 2 diabetes, impaired insulin sensitivity, and cognitive decline. Oxygen drops to dangerous levels hundreds of times per night. The heart works harder. The brain doesn't consolidate memory. Hunger hormones — ghrelin and leptin — are disrupted. Untreated sleep apnea actively works against any weight loss effort.
I had a split-night study at St. Joseph Hospital Sleep Center in Orange, California. The first 2.1 hours were diagnostic — no intervention, just monitoring. The numbers were not ambiguous.
One number that didn't show up in the primary stats but tells the full story: my sleeping heart rate was 92 bpm — identical to my waking rate. My heart never slowed down. My body never actually rested. It was in continuous emergency response mode all night, every night.
I should note: this study was done in April 2023. I had already been on GLP-1 therapy (Wegovy) for about five months at that point, and had lost more than 50 lbs before the study. What you're seeing above is after significant weight loss had already occurred. The baseline before GLP-1 was worse.
The second part of a split-night study is CPAP titration — they put the mask on and find the pressure that controls the apnea. My titration ran from midnight to 5 AM. Here is what happened to my sleep architecture in that same night.
That 39.8% REM is above the normal range of 15–25%. That's not a mistake — it's called REM rebound. When the brain has been chronically deprived of REM sleep, the moment it gets the chance, it floods into it. My brain was that starved. Five hours with CPAP produced more restorative sleep than years without it.
The prescribed device: ResMed AirSense 11 AutoSet. Pressure range 6–18 cm H₂O. EPR (expiratory pressure relief) of 3. AirFit P-10 nasal pillow mask. The AutoSet algorithm adjusts pressure dynamically every night — meaning the machine is continuously working to find the minimum effective pressure for my airway in real time.
Before CPAP, I never slept through the night. Not once. I would wake up four or more times, often needing to use the bathroom, and then stay awake for an hour or two before falling back asleep. I never woke up feeling rested. I thought that was just how I slept. I didn't know there was anything different to compare it to.
With CPAP, I sleep through the night. I wake up, and getting out of bed isn't a battle. I'm not dragging through the first two hours of every morning. The difference was not subtle. It was immediate and it was dramatic.
I'm 100% convinced that CPAP therapy has helped my weight loss. Sleep deprivation disrupts ghrelin and leptin — the hunger and satiety hormones. It drives cortisol up and insulin sensitivity down. When you're not sleeping, your body is fighting everything you're trying to do metabolically. I don't know exactly how much of my progress comes from the GLP-1 and how much comes from finally sleeping — but I know they're working together. That's real.
My CPAP machine uploads data to ResMed's MyAir platform every night. Three years of that data tells a story the scale alone doesn't show.
The number I watch most closely is the year-over-year AHI trend. Remember, this is AHI with the AutoSet machine working to control it — so even small changes are meaningful.
The 2026 AHI of 0.65 is the lowest annual average yet — and I'm the lightest I've been in 25 years. That is not a coincidence. As the weight comes off, the airway disease appears to be changing. The AutoSet is achieving control at progressively lower effective pressures. This is the follow-up sleep study conversation — I likely need a new baseline titration to recalibrate the pressure range to where my airway actually is now.
In December 2024, the FDA approved tirzepatide (Zepbound) specifically for the treatment of obstructive sleep apnea in adults with obesity — the first drug ever approved for that indication. The approval was based on the SURMOUNT-OSA trials, which showed significant AHI reductions alongside 18–20% weight loss. The mechanism is primarily through weight reduction — less tissue around the airway — but researchers are exploring whether GLP-1 receptors in the upper airway muscles may play a direct role as well.
A 2025 meta-analysis published in a peer-reviewed respiratory journal found that GLP-1 receptor agonists reduced AHI by an average of 16.6 events per hour compared to placebo across randomized controlled trials — a clinically significant reduction for anyone in the moderate-to-severe range.
A separate 2025 study presented at the American College of Chest Physicians found that type 2 diabetes patients on GLP-1 medications had substantially lower 1-year mortality than those not on GLP-1s — with a disproportionate benefit observed specifically in patients who also had obstructive sleep apnea. The researchers believe OSA patients may be among the biggest winners of GLP-1 therapy.
Important context: OSA is not exclusively an obesity issue, and weight loss alone doesn't resolve it for everyone. Anatomy — jaw structure, neck size, tongue position — plays a significant role. Some people with OSA are not overweight at all. What the research shows is that for people whose OSA is driven substantially by excess weight, GLP-1-driven weight loss can meaningfully reduce severity and, in some cases, resolve the condition.
I've lost nearly 100 lbs since my sleep study. The CPAP is still working — 99% of nights within normal AHI range — but I suspect the machine is working harder than it needs to. The AutoSet finds the right pressure each night, but my prescribed range (6–18 cm H₂O) was set for a 355-lb airway. My airway at 259 lbs is a different airway.
I'm planning a follow-up polysomnogram to establish a new baseline and give my sleep physician current data. I'm not expecting to come off CPAP entirely — at least not yet. But I'm realistic that the underlying condition has likely improved, and that there may be options that are less restrictive than where I started. A mandibular advancement device (MAD) is one possibility worth exploring at a lower AHI baseline. An updated titration study is the next step.
This page will be updated when I have those results. Real information means showing the full arc — not just the dramatic before/after, but the ongoing work of managing a chronic condition with the tools available and an honest assessment of where you are.
🔄 Living document. Last updated May 2026. Follow-up sleep study planned. This page will be updated with new titration data, any changes to therapy, and outcomes as the GLP-1 weight loss journey continues. Check the date above to know when you're reading current information.